Mavenclad benefits for MS sustained up to 15 years after last treatment
More than half who received it in clinical trials didn’t need further DMTs by Steve Bryson, PhD | April 11, 2023 The benefits…
Video: “BIOSIMILARS” – Learn ‘What is a Biosimilar medication’…
Click to Subscribe for the MS Beacon eNewsletter, resources and MS education Visit our MS Learning Channel on YouTube:…
Stuart Schlossman
video: Tips for accessing expensive MS medications on a limited budget – by Aaron Boster, MD
Click to watch, then share with others Click to Subscribe for the MS Beacon eNewsletter, resources and MS education Visit…
Stuart Schlossman
Tolebrutinib safely lowers relapse rates over 2.5 years
Phase 2b extension trial now has 125 MS patients on 60 mg daily dose About 2.5 years of treatment with tolebrutinib was…
Stuart Schlossman
Early treatment could slow the onset of multiple sclerosis symptoms, study finds
People with very early signs of MS who received the drug in a clinical trial were less likely to develop…
Stuart Schlossman
Interesting read: Learn about one of the newest MS medications – Tascenso-ODT (fingolimod)
To learn about Tascenso-ODT which was just approved in February 2023, click here Information provided by: Visit our MS…
Stuart Schlossman
Tenofovir Alafenamide for Treatment of Symptoms and Neuroprotection in Relapsing Remitting Multiple Sclerosis
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study…
Stuart Schlossman
Time to educate patients about biosimilars?
March 22, 2023 Today, the U.S. Food and Drug Administration released new educational materials for patients related to biosimilars and…
Stuart Schlossman
Are you on a Biologic Medication? What you need to know about biosimilar treatment options.
—————– Vea esta página en español The Food and Drug Administration (FDA) has approved many biologics (also called biological products),…
Stuart Schlossman
FDA Approves Tascenso ODT® (fingolimod), similar to Gilenya, for Relapsing MS
February 21, 2023 The U.S. Food and Drug Administration recently approved Tascenso ODT® (fingolimod, Cycle Pharmaceuticals) as an orally disintegrating tablet…
Stuart Schlossman
